TriSalus Life Sciences, Inc.
TLSI
$5.73
$0.081.42%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 12.41% | -0.20% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 12.41% | -0.20% | |||
| Cost of Revenue | 21.12% | 10.09% | |||
| Gross Profit | 11.03% | -1.66% | |||
| SG&A Expenses | 46.97% | -8.40% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 22.56% | -7.67% | |||
| Operating Income | -33.23% | 14.40% | |||
| Income Before Tax | -320.86% | 44.46% | |||
| Income Tax Expenses | 66.67% | -142.86% | |||
| Earnings from Continuing Operations | -321.34% | 44.62% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -321.34% | 44.62% | |||
| EBIT | -33.23% | 14.40% | |||
| EBITDA | -33.70% | 14.44% | |||
| EPS Basic | -227.24% | 43.74% | |||
| Normalized Basic EPS | -251.12% | 84.88% | |||
| EPS Diluted | -227.24% | 43.74% | |||
| Normalized Diluted EPS | -251.12% | 84.88% | |||
| Average Basic Shares Outstanding | 3.96% | 10.87% | |||
| Average Diluted Shares Outstanding | 3.96% | 10.87% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||